Search
Alkermes Plc
ALKSAdd to Watchlist
48.990USD
-1.040-2.08%
Close 07-31 16:00（ET）Quotes delayed by 15 min
8.11BMarket Cap
52.69P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Alkermes Plc is 8.11, ranking 170 out of 385 in the Biotechnology & Medical Research industry. The average price target is 45.00, with a high of 58.00 and a low of 30.00.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
55.098
Target Price
+13.98%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Alkermes Plc
ALKS
19
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Alkermes Plc's expected revenue for the next quarter?
Alkermes Plc's expected revenue is 465.47M.
What is Alkermes Plc's price target?
Analysts forecast that Alkermes Plc's price target is USD 45.00, with the highest forecast at USD 58.00 and the lowest forecast at USD 30.00.
What is the analyst rating for Alkermes Plc?
Based on the ratings of Alkermes Plc's stock from 19 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.